A higher proportion of patients receiving CILO/FIR as compared to placebo had ≥2 point reduction in NAS, as made evident by a reduction in steatosis, lobular inflammation, and ballooning and significantly improved AST, ALT, CK18, ELF score, and liver stiffness (all p ≤ 0.05). This evidence concerns the gene KRT18 and steatosis.